CD274 and neoplasm: PD-L1 IHC staining on tumor cells and/or tumor-infiltrating lymphocytes (TILS) is currently the gold standard eligibility assessment for ICB treatment, but its concordance with expression levels of the gene encoding PD-L1 (CD274) is not well established.